LON:COG Cambridge Cognition (COG) Share Price, News & Analysis → Move Your Money Before May 1 (From Stansberry Research) (Ad) Free COG Stock Alerts GBX 52 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range 51.62▼ 5350-Day Range 49.70▼ 57.8952-Week Range 47.23▼ 104Volume4,800 shsAverage Volume59,541 shsMarket Capitalization£18.18 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsHeadlinesStock AnalysisChartCompetitorsHeadlines Get Cambridge Cognition alerts: Email Address Ad Weiss RatingsThe Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.4 simple steps to protect your privacy and money before it’s too late. About Cambridge Cognition Stock (LON:COG)Cambridge Cognition Holdings Plc, a neuroscience technology company, develops and markets near-patient cognitive testing techniques in the United States, United Kingdom, the European Union, and internationally. The company offers CANTAB digital cognitive assessment platform for drug development by enabling pharmaceutical companies to take new therapeutics from preclinical consultancy to pivotal studies and approval, as well as supports sponsors to enhance recruitment, develop safe and effective treatments, and enhance research and development efficiency. It also provides CANTAB Connect Research, a proprietary platform that provides insights into behaviours, underlying brain circuits, and measurement of digital cognitive biomarkers; CANTAB Mobile, a touchscreen assessment of memory, mood, and functional status to detect the earliest signs of clinically relevant memory problems; CANTAB Insight to assess cognitive health; and CANTAB BrainHealth for assessing workplace wellbeing. In addition, the company offers electronic questionnaires and scales, a digital bespoke questionnaire; NeuroVocalix, a voice analysis platform to analyze voice to assess neurological change; cognition kit, a high frequency testing kit to detect changes over time and day-to-day cognition with short regular tests using patients' own devices. Cambridge Cognition Holdings Plc was incorporated in 2012 and is based in Cambridge, the United Kingdom.Read More COG Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart COG Stock News HeadlinesApril 25, 2024 | msn.comUniversity of Cambridge researchers use AI to find highly potent Parkinson’s drug candidates in a tenth of the usual timeApril 24, 2024 | msn.comBiogen reports sales of Alzheimer’s drug exceeded expectationsApril 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. April 23, 2024 | lse.co.ukCambridge Cognition partly-owned spin-off gets GBP1.5 million fundingApril 21, 2024 | thetimes.co.ukCambridge in free-speech row over researcher’s ‘race realism’ blogApril 17, 2024 | msn.comSage Therapeutics stock plunges 23 percent after Parkinson’s drug fails studyApril 17, 2024 | bizjournals.comSage halts trials in Parkinson’s after drug fails to show benefitApril 17, 2024 | msn.comAI speeds up drug design for Parkinson's by ten-foldApril 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. April 17, 2024 | msn.comA window into Alzheimer's and early detection - how regular eye exams could helpApril 15, 2024 | news.yahoo.comVision changes could predict dementia 12 years before diagnosis, study saysApril 11, 2024 | msn.com11 Greater Boston residents win Guggenheim Fellowships this yearApril 5, 2024 | yahoo.comTypes of dementia: From vascular to Alzheimer’sApril 3, 2024 | uk.news.yahoo.comHow food preferences are linked to cognition and brain health – and why a balanced diet is superiorApril 1, 2024 | msn.comThere’s a Reason They’re Called ‘Gut’ FeelingsApril 1, 2024 | msn.com"Beyond Words" brings actor's portrayal of a Harvard professor's parrot to Cambridge stageApril 1, 2024 | msn.comThese 79 Memes Are Just What You Need to Take a Break and Have a Giggle (New Pics)April 1, 2024 | msn.comDementia hope as scientists say jab could be huge 'breakthrough'April 1, 2024 | msn.comComforting hospital cat 'sucks up the negativity'April 1, 2024 | msn.comNew wonder jab to prevent dementia available on NHS in FIVE years - 'Massive breakthrough'March 31, 2024 | msn.comHuge Alzheimer's breakthrough as scientists say new jab could 'transform' livesMarch 31, 2024 | mirror.co.ukMajor Alzheimer's breakthrough as new vaccine could 'transform' lives, scientists sayMarch 29, 2024 | yahoo.comGoogle DeepMind CEO Demis Hassabis gets UK knighthood for 'services to artificial intelligence'March 29, 2024 | msn.comIt's Tricky to Know Which Supplements Are Safe — Here's What to AvoidMarch 28, 2024 | msn.comCanadian rower looking forward to third outing for Oxford in historic Boat RaceMarch 28, 2024 | msn.comChronic alcohol use is linked to impaired plasticity of brain inhibition networks, study suggestsMarch 21, 2024 | msn.comMemory-Boosting Supplements Could Lack Compounds and Contain BacteriaSee More Headlines Receive COG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cambridge Cognition and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/22/2020Today4/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Health Information Services Sub-IndustryN/A Current SymbolLON:COG CUSIPN/A CIKN/A Webwww.cambridgecognition.com Phone44 1223 810 700FaxN/AEmployees80Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.11) Trailing P/E RatioN/A Forward P/E Ratio37.97 P/E GrowthN/ANet Income£-3,740,000.00 Net Margins-29.25% Pretax MarginN/A Return on Equity-630.55% Return on Assets-13.31% Debt Debt-to-Equity Ratio18.95 Current Ratio0.45 Quick Ratio0.96 Sales & Book Value Annual Sales£12.77 million Price / Sales1.42 Cash FlowGBX 12.07 per share Price / Cash Flow4.31 Book ValueGBX 3 per share Price / Book17.33Miscellaneous Outstanding Shares34,960,000Free FloatN/AMarket Cap£18.18 million OptionableNot Optionable Beta0.76 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Matthew William Stork (Age 56)CEO & Director Comp: $342kMr. Stephen Daniel Symonds (Age 49)CFO & Executive Director Comp: $203.31kMr. John HammondCo-FounderMr. Nick TaptiklisHead of Technology StrategyMs. Francesca Cormack Ph.D.Chief Scientist & Member of Scientific Advisory BoardMr. Simon MerrittMarketing and Communications DirectorDr. Lisa Elizabeth Nolan Ph.D. (Age 62)Vice President Business Development Ms. Nicky AckerleyGlobal HR DirectorProf. Trevor Robbins CBEFBPsS, FMedSci, FRS, Ph.D., Senior ConsultantProf. Barbara Sahakian FBPsSFMedSci, Senior ConsultantMore ExecutivesKey CompetitorsFeedbackLON:FDBKInduction Healthcare GroupLON:INHCRenalytixLON:RENXOncimmuneLON:ONCOxford BioDynamicsLON:OBDView All Competitors COG Stock Analysis - Frequently Asked Questions How have COG shares performed in 2024? Cambridge Cognition's stock was trading at GBX 51.50 at the start of the year. Since then, COG shares have increased by 0.9% and is now trading at GBX 51.95. View the best growth stocks for 2024 here. How were Cambridge Cognition's earnings last quarter? Cambridge Cognition Holdings Plc (LON:COG) posted its earnings results on Tuesday, September, 22nd. The company reported ($1.50) earnings per share for the quarter. Cambridge Cognition had a negative trailing twelve-month return on equity of 630.55% and a negative net margin of 29.25%. What other stocks do shareholders of Cambridge Cognition own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cambridge Cognition investors own include Interserve (IRV), Alio Gold Inc. (ALO.TO) (ALO), Concepta PLC (CPT.L) (CPT), European Metals (EMH), IntelGenx Technologies (IGXT), Oxford Biomedica (OXB), Syneos Health (SYNH), Travelers Companies (TRV), Amryt Pharma (AMYT) and AltynGold (ALTN). How do I buy shares of Cambridge Cognition? Shares of COG stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:COG) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldMan Who Predicted 2008: “This Will be Worse.”AltimetryEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsTrump is sounding the alarmPreserve GoldJim Cramer’s “The Biggest Drug Ever”Behind the MarketsFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cambridge Cognition Holdings Plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
